Theravance Biopharma, Inc. (TBPH)

NasdaqGM • Currently up 0.02 (+0.12%) in today's trading session

1 member of Congress has disclosed 1 trade in Theravance Biopharma, Inc. (TBPH) via STOCK Act filings. The most recent disclosure was a sale by George Whitesides on 24 March 2025. Aggregate disclosed activity totals roughly $32.5K in sales (midpoint estimates from bracketed disclosure amounts).

Theravance Biopharma, Inc. is currently trading at $17.03, positioned at 50% of its 52-week range ($13.08 – $21.03).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Claim Free AssetCopy Portfolio

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Past Performance is not an indication of future results.

Current Price
$17.03
24h Change
+0.02 (+0.12%)
52 Week Range
$13.08—$21.03
View on NASDAQ

Theravance Biopharma, Inc. Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for TBPH

Select to highlight on chart
1 transactions
Compliance: 100%
George Whitesides24 Mar 202523 Apr 2025SaleStock$15,001 - $50,000N/A

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$882.64M

Volume

332.38K

Beta

0.17

P/E Ratio

-160.36

Fundamentals

EPS

$-0.11

Div. Yield

—

Open

$17.02

Day Range

$17.00 — $17.07

Company Information

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ · USD
Country
US
CEO
Rick E. Winningham
IPO Date
2014-05-16
Website
www.theravance.com

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary dise...

Earnings

Next Report

Q3 2026

10 Nov

EPS Est.

$0.24

Rev. Est.

$22M

Days Until

76

Recent Quarters

Q2 202610 Aug
EPS$-0.11
Miss 251.7%
Q1 20267 May
EPS$-0.10
Miss 443.6%
Q4 202519 Mar
EPS$0.06
Miss 86.4%
Q3 202510 Nov
EPS$0.04
Beat 133.3%
Q2 202512 Aug
EPS$1.08
Beat 1370.6%
Q1 20258 May
EPS$-0.27
Miss 31.2%
Q4 202426 Feb
EPS$-0.31
Miss 81.2%
Q3 202412 Nov
EPS$-0.26
Miss 12.6%
Q2 20245 Aug
EPS$-0.34
Miss 64.2%
Q1 202413 May
EPS$-0.24
Beat 5.0%
Q4 202326 Feb
EPS$-0.17
Miss 15.3%
Q3 20237 Nov
EPS$-0.17
Miss 70.0%
Q2 20237 Aug
EPS$-0.28
Miss 33.3%
Q1 20238 May
EPS$-0.35
Miss 29.6%
Q4 202227 Feb
EPS$-0.15
Beat 11.8%
Q3 20227 Nov
EPS$-12.14
Miss 6644.4%
Q2 20224 Aug
EPS$-0.11
Miss 83.3%
Q1 20225 May
EPS$-0.22
Miss 100.0%
Q4 202123 Feb
EPS$-0.43
Miss 30.3%
Q3 20213 Nov
EPS$-0.48
Beat 14.3%
Q2 20213 Aug
EPS$-0.80
Beat 20.0%
Q1 20214 May
EPS$-1.24
Miss 18.1%
Q4 202023 Feb
EPS$-0.92
Beat 9.8%
Q3 20205 Nov
EPS$-1.16
Miss 19.6%
Q2 20206 Aug
EPS$-1.00
Miss 2.0%
Q1 20206 May
EPS$-1.40
Miss 30.8%
Q4 201924 Feb
EPS$-1.17
Miss 3.5%
Q3 20195 Nov
EPS$-1.05
Beat 5.4%
Q2 201931 Jul
EPS$-0.72
Beat 41.9%
Q1 20197 May
EPS$-1.32
Miss 10.9%
Q4 201826 Feb
EPS$-0.92
Beat 13.2%
Q3 20186 Nov
EPS$-1.10
Beat 4.3%
Q2 20181 Aug
EPS$-0.76
Beat 36.7%
Q1 20188 May
EPS$-1.22
Beat 3.2%
Q4 201727 Feb
EPS$-1.64
Miss 41.4%
Q3 20177 Nov
EPS$-1.27
Miss 5.8%
Q2 20178 Aug
EPS$-1.27
Miss 11.4%
Q1 20179 May
EPS$-1.27
Miss 11.4%
Q4 201627 Feb
EPS$-1.36
Miss 29.5%
Q3 20168 Nov
EPS$-0.73
Beat 20.6%
Q2 20168 Aug
EPS$-1.06
Miss 0.9%
Q1 20169 May
EPS$-1.10
Miss 14.6%
Q4 20159 Mar
EPS$-1.23
Beat 23.6%
Q3 20159 Nov
EPS$-1.40
Beat 2.8%
Q2 201510 Aug
EPS$-1.42
Beat 6.0%
Q1 20157 May
EPS$-1.29
Beat 17.8%
Q4 201410 Mar
EPS$-2.02
Miss 18.8%
Q3 20146 Nov
EPS$-1.72
Beat 7.0%
Q2 201413 Aug
EPS$-1.83
Miss 215.8%
Q1 201424 Jun
EPS$-1.89
Miss 1990.0%
Q3 201331 Dec
EPS$-1.37
Q2 201330 Sept
EPS$-1.27
Q1 201330 Jun
EPS$-1.21
Q4 201231 Mar
EPS$-1.00
Q3 201231 Dec
EPS$-0.90
Q2 201230 Sept
EPS$-1.01

No dividend data available for this stock.

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations
No similar stocks found
No congressional trading patterns available for recommendations

Frequently Asked Questions about TBPH

Which members of Congress have traded TBPH?
1 member of Congress has disclosed 1 trade in Theravance Biopharma, Inc. (TBPH) under the STOCK Act: George Whitesides.
When was TBPH most recently disclosed by Congress?
The most recent TBPH disclosure was a sale by George Whitesides on 24 March 2025.
What is the total disclosed congressional trading volume for TBPH?
Members of Congress have disclosed approximately $32.5K in TBPH sales (midpoint estimate derived from the bracketed amount ranges used in STOCK Act filings).
How can I track new congressional trades in TBPH?
This TBPH page updates as soon as new STOCK Act disclosures are filed for Theravance Biopharma, Inc.. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
PoliticiansBillsArticlesPortfoliosPricingAboutLegalTerms of ServicePrivacy Policy
Français
© 2026 - All rights reserved. Powered by Vantara Labs
Pelosi Tracker is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office or her representatives, or with any other member of Congress. Any use of her name is solely for the purpose of discussing publicly available information.The information provided by Pelosi Tracker is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.